Merck Org Chart & Sales Intelligence blog

Merck & Co., Inc. Org Chart & Sales Intelligence Blog
Merck logo

Merck & Co., Inc.
126 East Lincoln Avenu
Rahway, NJ 07065
United States
Main Phone: 908-740-4000
Sector: Healthcare
Industry Sector: Healthcare - Drug Manufacturers
Full Time Employees: 67,000
CEO & Chairman: Robert M. Davis

Merck org chart & sales intelligence blog cover


Merck & Co., Inc., often referred to as Merck, stands as a worldwide pharmaceutical entity that has taken a leading role in pioneering healthcare progress for well over a century. Established back in 1891, Merck has established a formidable standing as an avant-garde figure in the realms of research, formulation, production, and promotion of an extensive spectrum of inventive prescription medications, vaccines, biologic treatments, and solutions for animal well-being.

Merck's operations encompass diverse business divisions, each catering to distinct healthcare necessities. Its human health sector is dedicated to unveiling, evolving, and distributing pioneering treatments and therapies spanning varied therapeutic domains such as cardiovascular ailments, oncology, immunology, infectious disorders, and diabetes. The company's vaccines segment is devoted to devising and disseminating vaccines designed to counteract diseases like HPV, pneumonia, hepatitis, and shingles. Furthermore, Merck's animal health sector extends a comprehensive selection of products and services aimed at safeguarding the health of livestock, pets, and other creatures.

Functioning as a worldwide healthcare enterprise, Merck extends its services to customers spanning across 140 countries, thus contributing significantly to the well-being of millions of individuals and animals around the globe. The company's expansive global footprint is fortified by an extensive network of manufacturing units, research hubs, and commercial operations, all working in concert to ensure the quality, production, and distribution of its offerings.

The bedrock of Merck's uniqueness in the industry rests in its steadfast commitment to research and development. The company allocates substantial resources to scientific innovation, perpetuating a robust pipeline brimming with potential novel medications, vaccines, and therapies. Merck's R&D endeavors are concentrated on cutting-edge technologies like immuno-oncology, biologics, and precision treatments, all oriented towards fulfilling unaddressed medical requirements and ameliorating patient outcomes.

Having etched an illustrious history, coupled with an unwavering dedication to scientific progression, a ubiquitous global presence, and a resolute focus on enhancing both human and animal well-being, Merck remains an indispensable protagonist in shaping the trajectory of healthcare, while simultaneously creating a positive impact in the lives of individuals and creatures spanning the world.

Merck 2022 Highlights


Fiscal Year
USD Currency
Fiscal Year Ends December 31, 2023
Most Recent Quarter  June 30, 2023
Profit Margin 5.34%
Operating Margin  14.87%
Management Effectiveness
Return on Assets  5.12%
Return on Equity  7.61%
Income Statement
Revenue  $58.31 Billion
Revenue Per Share  22.98
Quarterly Revenue Growth  3.00%
Gross Profit  42.08B
Net Income Avi to Common  3.11B
Diluted EPS  5.12
Balance Sheet
Total Cash  6.38B
Total Cash Per Share  2.51
Total Debt  36.91B
Total Debt/Equity  95.27%
Current Ratio  1.28
Book Value Per Share  15.24
Cash Flow Statement
Operating Cash Flow  15.08B
Levered Free Cash Flow  3.56B



Merck Board of Directors

Christine E. Seidman, M.D. Board Member (908) 740-4000 {first}.{last}
Douglas M. Baker, Jr. Board Member (908) 740-4000 {first}.{last}
Inge G. Thulin Board Member (908) 740-4000 {first}.{last}
Kathy J. Warden Board Member (908) 740-4000 {first}.{last}
Mary Ellen Coe Board Member (908) 740-4000 {first}.{last}
Pamela J. Craig Board Member (908) 740-4000 {first}.{last}
Patricia F. Russo Board Member (908) 740-4000 {first}.{last}
Paul B. Rothman, M.D. Board Member (908) 740-4000 {first}.{last}
Peter C. Wendell Board Member (908) 740-4000 {first}.{last}
Risa J. Lavizzo-Mourey, M.D. Board Member (908) 740-4000 {first}.{last}
Robert M. Davis Chairman and chief executive officer (908) 740-4000 {first}.{last}
Stephen L. Mayo, Ph.D. Board Member (908) 740-4000 {first}.{last}
Thomas H. Glocer Board Member (908) 740-4000 {first}.{last}


Merck Executive Leadership

Caroline Litchfield Executive vice president and chief financial officer (908) 740-4000 {first}.{last}
Chirfi Guindo Chief marketing officer, Human Health (908) 740-4000 {first}.{last}
Cristal N. Downing Executive vice president and chief communications & public affairs officer (908) 740-4000 {first}.{last}
Dave Williams Executive vice president, chief information & digital officer (908) 740-4000 {first}.{last}
Dean Y. Li, M.D., Ph.D. Executive vice president and president, Merck Research Laboratories (908) 740-4000 {first}.{last}
Jannie Oosthuizen President, Merck Human Health U.S. (908) 740-4000 {first}.{last}
Jennifer Zachary Executive vice president and general counsel (908) 740-4000 {first}.{last}
Joseph Romanelli President, Human Health International (908) 740-4000 {first}.{last}
Michael A. Klobuchar Executive vice president and chief strategy officer (908) 740-4000 {first}.{last}
Richard R. DeLuca, Jr. Executive vice president and president, Merck Animal Health (908) 740-4000 {first}.{last}
Robert M. Davis Chairman and chief executive officer (908) 740-4000 {first}.{last}
Sanat Chattopadhyay Executive vice president and president, Merck Manufacturing Division (908) 740-4000 {first}.{last}
Steven C. Mizell Executive vice president and chief human resources officer​ (908) 740-4000 {first}.{last}




Merck & Co Inc. Q1 2023 Earnings Results
Apr. 27, 2023

Executives in Attendance

  • Peter Dannenbaum - Vice President, Investor Relations
  • Robert Davis - Chairman and CEO
  • Caroline Litchfield - Chief Financial Officer
  • Dr. Dean Li - President, Merck Research Labs

Comments from Robert Davis - Chairman and CEO

Merck CEo Rob Davis

"By focusing on our science-led strategy, we intend to bring forward important innovation from our internal discovery pipeline and via strategic business development targeted at accessing the most compelling and complementary external science, leveraging our best-in-class clinical development capabilities. We aim to sustain the momentum in our pipeline in 2023 and beyond, and we're confident that this will lead to strong commercial and financial performance as well as value creation for patients and shareholders over the long term."

"We're very pleased with our announced acquisition of Prometheus Biosciences. Prometheus brings us a potential best-in-class novel treatment that could transform the standard of care for patients suffering from ulcerative colitis and Crohn's disease, potentially debilitating conditions as well as a broader pipeline and a technology platform that enables a precision medicine approach."

"We delivered very significant underlying growth, excluding the expected year-over-year decline in LAGEVRIO sales. This reflects continued fundamental strength and momentum across our key growth drivers particularly in oncology and vaccines. These results reinforce our confidence in the robust demand for our innovative portfolio and in our outlook for the remainder of 2023."

"We feel very good about the progress we've made in a very short period of time. So if you look at the opportunity to be in a situation to have sustainable growth well into the next decade. We feel like we've made significant progress. Whether it's the deal with Acceleron and then I would add the broad and strong internal pipeline we have in cardiovascular that as you know, we've indicated has 8 potential launches in the '24 to '28 timeframe, which has the potential to generate more than $10 billion as we move into the mid-2030s."

Strategic Priorities

Merck Q1 2023 Financials



Merck Technographic profile



Strong Brand and Reputation: Merck & Co. has established itself as a trusted and respected brand in the pharmaceutical industry, known for its high-quality products and commitment to scientific excellence.

Robust Research and Development: Merck invests significantly in research and development, leading to a strong pipeline of innovative drugs and therapies. This focus on R&D allows the company to stay at the forefront of scientific advancements and bring new treatments to market.

Diversified Product Portfolio: Merck has a diversified portfolio spanning various therapeutic areas, including cardiovascular diseases, oncology, immunology, infectious diseases, and diabetes. This diversification reduces the company's reliance on any single product and provides a broader market reach.

Global Presence: Merck operates in over 140 countries, allowing it to reach a wide customer base and access diverse markets. Its global presence provides opportunities for growth and adaptation to local market dynamics.


Patent Expirations: Like other pharmaceutical companies, Merck faces the challenge of patent expirations, which can lead to the entry of generic competitors and a loss of market exclusivity for certain products.

Pricing Pressures: The pharmaceutical industry faces ongoing pricing pressures, with governments and healthcare systems demanding lower drug prices. These pricing pressures can impact Merck's profitability and market share.


Emerging Markets: Expanding into emerging markets presents significant growth opportunities for Merck. Rising healthcare spending, increasing access to healthcare, and evolving regulatory environments in countries like China, India, and Brazil offer new market potential.

Advancements in Technology: Technological advancements, such as precision medicine, gene therapies, and digital health solutions, present opportunities for innovation and the development of new therapies. Merck can leverage these advancements to enhance its product offerings and improve patient outcomes.


Generic Competition: The pharmaceutical industry is susceptible to competition from generic drug manufacturers, especially when patents expire. Generic competitors can offer lower-cost alternatives, impacting Merck's market share and revenue.

Regulatory and Legal Challenges: Merck operates in a highly regulated environment and faces legal challenges such as patent disputes, product liability claims, and regulatory changes. Compliance with evolving regulations and legal battles can impact the company's operations and financial performance.

Healthcare Reform: Changes in healthcare policies and reforms, particularly in major markets like the United States, can impact Merck's pricing negotiations, market access, and profitability.

Merck's ability to leverage its strengths, address weaknesses, capitalize on opportunities, and navigate threats will be critical to its long-term success in the pharmaceutical industry.


Political Factors:

Government Regulations: The pharmaceutical industry is heavily regulated, and changes in regulations regarding drug approvals, intellectual property rights, pricing, and advertising can significantly impact Merck's operations and market access.

Healthcare Policies: Government policies and healthcare reforms, such as changes in reimbursement systems, pricing controls, and public healthcare programs, can influence the demand for pharmaceutical products and pricing negotiations for Merck.

Economic Factors:

Economic Conditions: Economic factors such as GDP growth, inflation rates, and healthcare spending levels can impact the affordability and demand for Merck's products. Economic downturns or recessions may lead to reduced healthcare spending, affecting the company's revenue.

Currency Fluctuations: As a global company, Merck's operations and financial performance can be influenced by currency exchange rate fluctuations, affecting its revenue and profitability in different markets.

Social Factors:

Aging Population: The global aging population presents both opportunities and challenges for Merck. Age-related diseases and conditions create a larger market for the company's products, particularly in areas such as cardiovascular health, neurology, and chronic diseases.

Health Consciousness: Increasing consumer awareness and focus on health and wellness can drive demand for Merck's preventive healthcare products and services. The trend towards personalized medicine and patient-centric care also presents opportunities for the company.

Technological Factors:

Advances in Research and Development: Technological advancements, such as genomics, proteomics, and digital health solutions, can enhance Merck's research and development capabilities, leading to the discovery of innovative therapies and treatments.

Digital Transformation: The digitalization of healthcare, including telemedicine, electronic health records, and mobile health applications, can impact Merck's business processes, clinical trials, supply chain management, and patient engagement.

Environmental Factors:

Environmental Regulations: Increasing focus on environmental sustainability and regulations related to waste management, greenhouse gas emissions, and sustainable sourcing can impact Merck's manufacturing processes, supply chain practices, and product development.

Legal Factors:

Intellectual Property Protection: Intellectual property rights and patent protection are crucial for the pharmaceutical industry. Changes in intellectual property laws or challenges to existing patents can impact Merck's competitive position and profitability.

Product Liability and Safety: Stringent regulations and potential product liability claims impose legal obligations on Merck to ensure the safety and quality of its products. Compliance with regulations and maintaining a strong safety record is essential.



Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Apr 2023

Merck acquires Prometheus

Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (ìPrometheusî) (Nasdaq: RXDX) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

"At Merck, we are committed to delivering on our purpose to save and improve lives and continue to identify and secure opportunities where compelling science and value creation align," said Robert M. Davis, chairman and chief executive officer, Merck. "The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need. This transaction adds diversity to our overall portfolio and is an important building block as we strengthen the sustainable innovation engine that will drive our growth well into the next decade."


Accelerating Merckís journey to cloud for continuous modernization
Dec 2022

HCL Tech Cloud Smart

In a shared session at AWS re:Invent, Merck shared the impact of adopting continuous modernization for the cloud with the help of HCLTech.The key drivers for embarking on this cloud transformation journey were flexibility, scale, speed-to-market and continuous innovation, with the ultimate aim of improving the delivery and innovation of life saving products.

Building on an established 17-year relationship, HCLTech was well positioned to help Merck achieve this objective and accelerate the adoption of cloud as a business platform. Once the business goals and ambition had been established, HCLTech established an application migration and modernization foundation that enabled continuous modernization of applications and platforms on the AWS Cloud.This migration was delivered in an agile DevSecOps model with Continuous Integration and Continuous Delivery (CI/CD) pipelines and HCLTech.

- HCLTech brought in historical knowledge of Merckís applications and infrastructure.
- Analyzed 2,000+ apps and identified 300+ apps for migration and modernization of on-premise workloads to the cloud.
- Created an innovative path to increase modernization.
- Modernized Merckís core enterprise platforms (Tibco and SAP)
- Committed multi-million-dollar savings over five years.
- Implemented retire, re-architect, replatform and refactor of legacy assets across the business units.
- Implemented continuous automation and building of reusable components for driving efficiency post-modernization.
- Sprint-based DevSecOps framework for continuous delivery and improvement.


Merckís cloudification strategy sets example for others in critical industries
Dec 2022


Organizations in sensitive industries, such as healthcare, have to ensure that their cloud transformations bring dividends in two areas: the financial side and saving lives. Pharmaceutical company Merck & Co Inc. has seen its move to the cloud happen gradually at scale to ensure it fulfills both of the aforementioned areas.

"When we talk about moving things to the cloud, it's much more than just moving servers or things like that," said Ron Kim, Chief Technology Officer and Senior Vice President at Merck. "It's really contributing towards our business that saves and improves lives. So for our work, the stakes are high, but we think the opportunity's great. And seizing that opportunity is what we're doing now with our Blue Sky program and working with AWS and Accenture on it."


Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
Jun 2022
Merck announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck.


Merck Improves Speed and Reduces Manual Effort to Assess Change Proposals Up to 70% on AWS
Merck used AWS to build the Change Assessment Knowledge Engine (CAKE). CAKE helps chemistry, manufacturing, and control scientists make change assessments more quickly, effectively, and consistently, says John Baker, executive director of machine learning and analytics at Merck. CAKE reduced change assessment duration by up to 90 percent and total manual effort per assessment by 30-70 percent. Merck developed and implemented its CAKE pilot in less than 10 months using AWS, and in 2021, the company planned to execute a global rollout.


How Merck's CIO/CDO is Driving IT Agility with a Product Mindset
Jul 2021

Merck CIO David Williams

Dave Williams, Chief Information and Digital Officer of Merck, gives his perspective on the similarities and differences between the CIO and CDO roles and the way they relate to driving business transformations. Within Merck, Dave speaks to the insights arising from the companyís transition from a project-focused to product-focused model, the advantages from its investment in cloud technology, and the use of data analytics and AI/ML to make decisions and assess risks.



More on Merck

Merck Contact Info
Merck Org Charts on Corporate Structure, Executive Leadership, Marketing, Finance, HR, Supply Chain, Technology, R&D, Manufacturing, etc
Merck Financial Insights
Merck SWOT Analysis
Merck PESTLE Analysis
Merck Technographic Profile
Merck IT Budgets
Merck Executive Profiles
Merck Sales Trigger Events

About databahn
databahn builds customized deep dive account intelligence reports to help sellers and ABM marketers eliminate costly research time and build pipeline opportunities. databahn focuses on large and complex Fortune 500, Fortune 1000, Global 2000, State Government, and Higher Education organizations. databahn's highly experienced research team is located in beautiful Nashua, New Hampshire. For more information, please email